FDA Files Corcept’s New Drug Application for Relacorilant as a Treatment for Patients with Platinum-Resistant Ovarian Cancer
CORT(NASDAQ:CORT) REDWOOD CITY, Calif.--(BUSINESS WIRE)--Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the U.S. Food and Drug Administration (FDA) has accepted Corcept’s New Drug Application (NDA) for relacorilant as a treatment for patients with platinum-resistant ovarian cancer
Corcept Therapeutics Therapy Fails Primary Goal But Extends Patient Survival In Amyotrophic Lateral Sclerosis Study
CORTCorcept's ALS drug dazucorilant improved survival despite missing the main goal; ovarian cancer drug combo met its target in Phase 3.
Corcept Therapeutics Presented Results From Its DAZALS Study Of Dazucorilant In Patients With ALS At The European Network To Cure ALS 2025 Annual Meeting, DAZALS Did Not Meet Its Primary Endpoint Of Improved Outcome In The Als Functional Rating Scale-revi
CORTCorcept Therapeutics Reports Phase 3 ROSELLA Trial Results As Relacorilant Plus Nab-Paclitaxel Improves Survival In Platinum-Resistant Ovarian Cancer Without Added Side Effects, Showing 30% Reduced Progression Risk And 31% Lower Death Risk In ASCO 2025 La
CORTHere's How Much $1000 Invested In Corcept Therapeutics 5 Years Ago Would Be Worth Today
CORTHere's How Much You Would Have Made Owning Corcept Therapeutics Stock In The Last 5 Years
CORTHow Do Investors Really Feel About Corcept Therapeutics?
CORTAssessing Corcept Therapeutics: Insights From 9 Financial Analysts
CORTHC Wainwright & Co. Maintains Buy on Corcept Therapeutics, Lowers Price Target to $145
CORT12 Health Care Stocks Moving In Monday's After-Market Session
CORTCorcept Therapeutics Affirms FY2025 Sales Guidance of $900.00M-$950.00M vs $905.38M Est
CORTCorcept Therapeutics Q1 EPS $0.17 Beats $0.14 Estimate, Sales $157.21M Miss $177.94M Estimate
CORTHere's How Much $1000 Invested In Corcept Therapeutics 10 Years Ago Would Be Worth Today
CORTCorcept To Present Late-Breaking Data From Pivotal Phase 3 ROSELLA Trial Of Relacorilant In Platinum-Resistant Ovarian Cancer At ASCO 2025
CORTCorcept Therapeutics Announces Publication Of Findings From Prevalence Phase Of CATALYST Trial In Diabetes Care
CORT$1000 Invested In Corcept Therapeutics 20 Years Ago Would Be Worth This Much Today
CORTCorcept Begins Trial Of Relacorilant Plus Nab-Paclitaxel And Bevacizumab For Patients With Platinum-Resistant Ovarian Cancer
CORTCanaccord Genuity Maintains Buy on Corcept Therapeutics, Raises Price Target to $142
CORTDeep Dive Into Corcept Therapeutics Stock: Analyst Perspectives (7 Ratings)
CORTCorcept Therapeutics Stock Jumps On Upbeat Ovarian Cancer Trial Data, Analysts Boost Price Forecast
CORTCorcept's ROSELLA trial met its primary endpoint, showing relacorilant improved progression-free and overall survival in platinum-resistant ovarian cancer.
Truist Securities Maintains Buy on Corcept Therapeutics, Raises Price Target to $150
CORTHC Wainwright & Co. Maintains Buy on Corcept Therapeutics, Raises Price Target to $150
CORTNasdaq Tumbles Over 300 Points; Chicago PMI Rises In March
CORTCorcept Therapeutics Met Primary Endpoint In Phase 3 ROSELLA Trial of Relacorilant in Patients with Platinum-Resistant Ovarian Cancer
CORTPiper Sandler Maintains Overweight on Corcept Therapeutics, Raises Price Target to $78
CORTHC Wainwright & Co. Reiterates Buy on Corcept Therapeutics, Maintains $115 Price Target
CORTCorcept Therapeutics Q4 2024 GAAP EPS $0.26 Misses $0.42 Estimate, Sales $181.900M Miss $198.686M Estimate
CORTHC Wainwright & Co. Reiterates Buy on Corcept Therapeutics, Maintains $80 Price Target
CORTPreview: Corcept Therapeutics's Earnings
CORTCorcept Therapeutics (NASDAQ:CORT) is set to give its latest quarterly earnings report on Thursday, 2022-05-05. Here's what investors need to know before the announcement.
Analysts estimate that Corcept Therapeutics will report an earnings per share (EPS) of $0.24.
